Results 211 to 220 of about 3,949,650 (302)

Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT

Journal of Medicinal Chemistry, 1993
A novel series of dual-labeling D2 dopamine agents (labeled with either 18F or 123I for PET or SPECT imaging, respectively) was investigated. Two desired fluorinated and iodinated dopamine agents, FIDA1, (S)-(-)-2-(2-fluoroethoxy)-5-iodo-3-methoxy-N-[(1-ethyl-2- pyrrolidinyl)methyl]-benzamide, and FIDA2, (R)-(+)-2,3-dimethoxy-5-iodo-N-[(1-(4 ...
S, Chumpradit, M P, Kung, J, Billings, R, Mach, H F, Kung   +4 more
openaire   +3 more sources

Dopamine D3 receptor antagonists as therapeutic agents

Drug Discovery Today, 2005
The behavioral and pathophysiological role of the dopamine D(3) receptor, which was deduced from anatomical, lesion and drug treatment studies in the ten years following cloning of the receptor, indicated that its functions differed from those of the D(2) receptor.
Jeffrey N, Joyce, Mark J, Millan
openaire   +3 more sources

Clinical Pharmacology of Dopamine-Modulating Agents in Tourette’s Syndrome

International review of neurobiology, 2013
Forty years of research and clinical practice have proved dopamine (DA) receptor antagonists to be effective agents in the treatment of Tourette's syndrome (TS), allowing a significant tic reduction of about 70%. Their main effect seems to be mediated by the blockade of the striatal DA-D2 receptors. Various typical and atypical agents are available and
Sabine, Mogwitz, Judith, Buse, Stefan, Ehrlich, Veit, Roessner   +3 more
openaire   +3 more sources

IV inotropic agents: dopamine, dobutamine, and amrinone

Critical Care Nurse, 1990
Three commonly used IV inotropic agents--dopamine, dobutamine, and amrinone--have been discussed in this article. Knowledge of their common mechanisms of action, individual actions, dosages, methods of preparation, precautions, and side effects can only help critical care nurses maintain or improve the quality of care given to patients receiving these ...
J, Budny, K, Anderson-Drevs
openaire   +2 more sources

Dopamine D2 receptor agents, but not dopamine D1, modify brain glucose metabolism

Brain Research, 1985
The effects of recently described selective dopamine D1 and D2 agonists and antagonists on brain glucose metabolism were studied using the 2-[14C]deoxyglucose autoradiographic technique. The administration of LY-141865 or YM-09151-2, which behave as a specific D2 agonist and antagonist respectively, modified brain glucose metabolism in a manner similar
J M, Palacios, K H, Wiederhold
openaire   +2 more sources